Illumina, Inc. (NASDAQ: ILMN) today announced new customer breakthroughs in oncology powered by Illumina's spatial transcriptomics, 5-base sequencing, and proteomics technologies. The ability to ...

The collaborations will provide Illumina's customers with workflows for genomic disease characterization and spatial mapping.

At AGBT, customers will present data demonstrating unparalleled scale and sensitivity in research spanning pulmonary fibrosis, prostate cancer, and 3D reconstructions of mouse brains Company expands ...

40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaSeq X systems, advancing ...

AGBT is also, increasingly, a showcase for instruments for spatial biology, a fast-growing field that involves pinpointing ...